Roche/Ex­elix­is' Cotel­lic fiz­zles in piv­otal melanoma study

To lit­tle sur­prise, Ex­elix­is’ Cotel­lic — known chem­i­cal­ly as co­bime­tinib — in com­bi­na­tion with Roche’s Tecen­triq, has failed a late-stage study as a front­line treat­ment for pa­tients …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER